| Ankylosing spondylitis
Celebrex vs Cyltezo
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Celebrex vs Cyltezo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCyltezo has a higher rate of injection site reactions vs Celebrex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cyltezo but not Celebrex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Celebrex
Cyltezo
At A Glance
Oral
Once or twice daily
COX-2 inhibitor
SC injection
Every other week
TNF-alpha inhibitor
Indications
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Ankylosing spondylitis
- Primary dysmenorrhea
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Panuveitis
Dosing
Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.
Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.
Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.
Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.
Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg every other week SC; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Crohn Disease, Ulcerative Colitis 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week SC starting Day 29.
Psoriasis vulgaris, Panuveitis 80 mg initial dose, then 40 mg every other week SC starting 1 week after initial dose.
Contraindications
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Setting of CABG surgery
- Demonstrated allergic-type reactions to sulfonamides
—
Adverse Reactions
Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, accidental injury, nausea, urinary tract infection, flu syndrome, abdominal pain, hyperlipidemia, back pain, hypertension, hematuria
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, acute liver failure, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis
Pharmacology
Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.
Adalimumab-adbm is a TNF-alpha antagonist that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, modulating inflammatory responses and reducing concentrations of acute phase reactants such as CRP and ESR.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Celebrex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (4/12) · Qty limit (11/12)
Cyltezo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Celebrex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Cyltezo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Celebrex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Cyltezo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Celebrex.
No savings programs available for Cyltezo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CelebrexView full Celebrex profile
CyltezoView full Cyltezo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.